Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

everlinQ Endovascular Access System Enhancements (EASE) Study

NCT03708770 is registered in ClinicalTrials.gov with C. R. Bard as lead sponsor.

NCT NCT03708770
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03708770 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
everlinQ Endovascular Access System Enhancements (EASE) Study
Lead sponsor
C. R. Bard
Phase
Not applicable
Overall status
Completed
Start date
July 27, 2015
Completion date
June 19, 2017
Enrollment
32 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

chronic kidney diseases